VERVE-102 is an investigational, in vivo base editing therapy designed to permanently turn off the PCSK9 gene in the liver, offering a potential one-time treatment for heterozygous familial ...
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort ...
Eli Lilly and Company says it will acquire the gene therapy start-up Verve Therapeutics for $1.3 billion. Verve’s lead drug candidate, VERVE-102, turns off the PCSK9 gene in the liver to reduce LDL-C ...
(Bloomberg) -- Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its ...
Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion, the companies said today, in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback